middle.news
InhaleRx Secures $38.5M to Accelerate Inhaled Cancer Pain and Anxiety Drug Trials
11:42am on Thursday 23rd of January, 2025 AEDT
•
Healthcare
Read Story
InhaleRx Secures $38.5M to Accelerate Inhaled Cancer Pain and Anxiety Drug Trials
11:42am on Thursday 23rd of January, 2025 AEDT
Key Points
Secured $38.5 million funding agreement with Clendon Biotech Capital
Phase 2 trial for IRX-211 expanded to 156 patients to enhance efficacy detection
Filed international PCT patent application for inhaled breakthrough cancer pain treatment
Appointed Ingenu CRO to oversee clinical trials, pending shareholder approval
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Inhalerx (ASX:IRX)
OPEN ARTICLE